Simple tumor enucleation may not decrease oncologic outcomes for T1 renal cell carcinoma: a systematic review and meta-analysis
Urologic Oncology: Seminars and Original Investigations Aug 24, 2017
Cao DH et al. – A systematic review and meta–analysis was performed to evaluate the clinical efficacy and safety of simple tumor enucleation (TE) for clinical T1 renal cell carcinoma. The authors concluded that TE is an effective and safe treatment for T1 renal tumors compared to traditional Partial Nephrectomy (PN) and has acceptable early oncology outcomes. However, these findings have to be validated through well designed studies.
- The aim was to identify all trials that compared TE and traditional PN in patients with clinical T1 renal cell carcinoma through a systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases.
- A total of 3,218 patients were identified through 7 studies in this meta–analysis.
- The TE group had significantly shorter operation times (mean difference [MD] = -21.93), shorter warm ischemia times (MD = -1.96), less blood loss (MD = -36.63), and lower surgical complication rates (odds ratio [OR] = 0.66) compared with the PN group.
- No significant difference was found between the 2 groups in hospital stay duration, changes in estimated glomerular filtration rate, positive surgical margin rates, and local recurrence rates.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor